Cannabis clinical research, mapped to the human body.

This registered clinical trial is investigating whether a combined intervention can help young adults who experience problems with alcohol and cannabis use, as well as sleep difficulties, to reduce these issues. The study aims to recruit 800 participants to evaluate the effectiveness of this intervention.

This study is investigating whether long-term use of cannabidiol (CBD) oral solution could lead to chronic liver damage or scarring in patients being treated for severe seizure disorders.

This registered trial aims to assess the effectiveness and feasibility of using oral cannabis extracts, specifically CBD and THC, for managing pain associated with osteoarthritis of the hip and/or knee. It compares these cannabinoids against a placebo to evaluate their impact on pain interference.

This registered trial investigates whether a single 600mg dose of CBD can enhance the extinction of conditioned fear responses in college students with social anxiety, compared to a placebo. Participants will undergo a fear conditioning paradigm, followed by either CBD or placebo, and their fear extinction will be measured.

This randomized controlled trial investigated the effectiveness of oral cannabidiol (CBD) for treating myofascial pain disorder in the temporomandibular region. It compared CBD to a placebo (hemp seed oil) to see if it could reduce pain and improve jaw function over a three-month period.

This is a randomized, placebo-controlled study investigating how different doses of CBD affect pain and opioid cravings in outpatients with opioid use disorder who are already receiving medication for their condition.

This is an active, not yet recruiting, pilot clinical trial investigating the therapeutic effects of a full-spectrum cannabis extract with varying doses of CBD and THC on fibromyalgia symptoms in cisgender women. The study aims to determine if cannabinoids can reduce pain, fatigue, and other symptoms while improving quality of life, with dose adjustments based on clinical response over six months.

This registered trial is investigating the safety and effectiveness of a fixed-dose cannabis inhaler containing THC as an add-on treatment for diabetic peripheral neuropathic pain. Participants will receive different doses of THC or a placebo, with pain intensity being the primary measure at 15 weeks.

This study investigated how social and substance use-related risks, including cannabis use, are associated with the duration of untreated psychosis (DUP) in patients with psychotic disorders. Researchers identified distinct groups of patients based on these risk factors and examined their impact on how long psychosis goes untreated. The findings highlight the importance of considering multiple social and substance use factors when addressing DUP.

This retrospective study investigated whether cannabis intoxication affected the nutritional status of adult burn patients with less than 20% total body surface area (TBSA) burns. Researchers compared 76 cannabis-positive patients to 76 cannabis-negative controls, analysing markers like prealbumin and albumin levels. The study found no significant impact of cannabis on nutritional status in this patient group.

This ecological momentary assessment study investigated the relationship between negative mood and cannabis use in pregnant individuals. It found that higher levels of depression, anxiety, and irritability predicted subsequent cannabis use, and that cannabis use was followed by a reduction in these negative moods.

This ecological study in Denmark investigated the relationship between increasing cannabis potency and psychiatric harms over 23 years. It found a significant increase in THC concentration in seized cannabis resin, which was positively associated with increased rates of cannabis treatment admissions, cannabis-induced psychosis, and dual diagnoses (schizophrenia and cannabis use disorder) at the population level.

This study describes a protocol for gathering user feedback on a digital tool called the Chronic Pain Recommendation Map, which includes information on cannabis for chronic pain management. The aim is to refine the tool's design, usability, and content based on perspectives from various stakeholders, including patients and healthcare providers.

This systematic review and meta-analysis investigated the effects of tetrahydrocannabinol (THC) on intraocular pressure (IOP) in humans. It found that THC significantly reduced IOP overall, with the intravenous route showing the most significant reduction, but the effect was not always significantly different from controls.

This rapid review evaluates the efficacy and safety of high-THC medicinal cannabis products, particularly those with THC concentrations of 16%-22%, in adult populations. It found mixed outcomes for various conditions and noted adverse events like psychiatric and gastrointestinal effects, highlighting a lack of studies on products with very high THC concentrations (above 22%).

This observational study examined the long-term effects of daily cannabis use, with and without concurrent cocaine use, among people living with HIV. It looked at how cannabis use impacts symptoms like sleep, pain, and anxiety, as well as healthcare visits. The study found that less frequent cannabis use was linked to fewer HIV clinic visits.

This study investigated differences in the expression of genes related to the endocannabinoid system in the brains of individuals with alcohol use disorder (AUD) compared to healthy controls. It found significant alterations in the expression of cannabinoid receptors and endocannabinoid-metabolizing enzymes in specific brain regions. These findings suggest the endocannabinoid system plays a role in AUD.

This study examined how race influences the connection between anxiety sensitivity and the choice of substance among veterans seeking treatment for substance use. It included participants who primarily used cannabis, stimulants, or opioids, and found that Black individuals reported higher anxiety sensitivity and had different substance preferences compared to White individuals. While anxiety sensitivity wasn't directly linked to substance choice, race played a significant role.

This review explores the potential of cannabinoids and endocannabinoid system (ECS) modulators as treatments for cardiac remodelling and fibrosis, conditions that are significant prognostic factors after myocardial infarction or in chronic diseases like hypertension and diabetes. The authors suggest that compounds with anti-inflammatory and antioxidant properties, such as cannabinoids, could offer therapeutic benefits by influencing pro-fibrotic signalling and inhibiting extracellular matrix deposition in the heart.

This study investigated how neuropeptides and the endocannabinoid system affect blood pressure in adolescents with primary hypertension. It found lower levels of certain neuropeptides in obese hypertensive patients and suggests the endocannabinoid system may also play a role in blood pressure regulation.

This study investigated the impact of preoperative cannabis use on outcomes following anterior cervical diskectomy and fusion (ACDF) surgery. It found that patients who used cannabis before surgery had a higher risk of various medical and surgical complications, including the need for revision surgery. The findings suggest that cannabis use may be a modifiable risk factor for ACDF outcomes.

This study investigated whether cannabis use, similar to tobacco use, increases the risk of adverse events after total hip arthroplasty (THA). Researchers compared outcomes in non-users, tobacco users, tobacco and cannabis users, and cannabis-only users. The findings suggest that cannabis-only users do not experience a significantly increased risk of adverse events after THA, unlike tobacco users.

This study investigated the association between cannabis use disorder (CUD) and the risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). It found that patients with both T2DM and CUD had a significantly higher risk of developing DR and its severe forms compared to those with T2DM alone.

This study examines the prevalence of cannabidiol (CBD) use among pregnant women and women of reproductive age in the United States using national survey data. It highlights that a significant proportion of these women have used CBD, despite clinical guidelines recommending against it during pregnancy and lactation. The authors suggest that clinicians should screen for CBD use to counsel patients about potential risks.

This randomized, placebo-controlled study investigated the acute effects of dronabinol (synthetic THC) and hydromorphone, alone and in combination, on pain and other measures in individuals with knee osteoarthritis. The study aimed to understand their analgesic properties and potential for extramedical use. The findings indicated that neither substance alone nor in combination provided robust pain relief for experimentally induced pain.

This review explores potential pharmacokinetic (PK) drug-drug interactions between major cannabinoids (THC, CBD, CBN, CBC, CBG) and commonly prescribed medications. It highlights the importance of understanding these interactions, especially with the increasing use of cannabis for both medical and recreational purposes. The review focuses on interactions relevant to cardiovascular, metabolic, and psychiatric treatments, as well as those used for pain, epilepsy, and cancer.

This study examines the prevalence and characteristics of cannabis use among pregnant individuals in the U.S. It found that nearly 7% of pregnant participants reported current cannabis use, with certain sociodemographic and clinical factors associated with higher rates of use. The research suggests a need for targeted interventions to address cannabis use during pregnancy.

This study compared chronic cannabis users, ayahuasca users, and non-users to understand long-term neuropsychological and personality effects. It found no significant cognitive differences between cannabis users and non-users. However, personality traits, such as novelty seeking and impulsive nonconformity, distinguished cannabis users from non-users.

This study analyzed Canadian survey data from 2012 and 2022 to examine associations between cannabis use frequency and generalized anxiety disorder, major depressive episodes, and suicidality. It found that higher cannabis use frequency was consistently associated with a higher prevalence of these mental health issues, and these associations strengthened over the decade. The findings suggest a need for increased investment in early identification and integrated treatment for co-occurring cannabis use and mental health problems.

This program evaluation studied the feasibility of reimbursing medical cannabis for chronic pain within a workers' compensation system in Colorado. The patient reported significant improvements in pain, function, and quality of life, alongside a modest reduction in opioid use, with no adverse safety events.